Merck pipeline update: ESA development ditched because of regulatory hurdles
This article was originally published in Scrip
Executive Summary
Merck & Co has discontinued the development of its erythropoiesis-stimulating agent (ESA) MK-2578, for the treatment of anaemia, citing delays caused by the new regulatory restrictions the US FDA has enforced to address the cardiovascular risks associated with the drug class as the reason.